शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSECCME Global Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 14 Nov, 2025 · 18:25 IST

Financial Results for the quarter ended on 30.09.2025

Net loss reportedNegative operating cash flowGoing-concern doubtResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.5%Reaction day
₹174.10
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-2.1% vs market
Pharmaceuticals & Biotechnology peers, median of 162sector · industry level+0.1%-1.6% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.5+0.6-2.1+0.1-1.6
Next day
-3.4-0.2-3.2-0.7-2.8
2d
-5.4-0.4-5.0-1.2-4.2
3d
-7.2-0.7-6.5-1.1-6.2
4d
-9.1-2.2-6.9-2.0-7.1
5d
-10.9-2.8-8.1-3.2-7.7
1w
-14.4-1.4-13.0-2.2-12.2
15d
-39.3-7.0-32.3-4.9-34.4
1m
-51.2-6.1-45.1-5.5-45.7
2m
-56.9-9.2-47.7-7.8-49.1
3m
-62.3-6.8-55.4-9.6-52.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Genesis IBRC India Ltd reported a net loss of Rs 6.47 lakhs in Q2 FY26 and Rs 18.28 lakhs for H1 FY26, sharply reversing a profit of Rs 355.34 lakhs in H1 FY25. Total income from operations for the half-year stood at Rs 366.72 lakhs, while total expenses were Rs 18.28 lakhs. The company's other equity is deeply negative at Rs (465.02) lakhs as of 30 September 2025, indicating accumulated losses far exceed share capital. Cash and cash equivalents rose to Rs 8.33 lakhs, but cash flow from operations was negative at Rs (15.45) lakhs for the half-year. The statutory auditor (M.N. Rao & Associates LLP) issued an unmodified limited review report with no qualifications.

Likely market impact

The swing from profit to loss combined with persistently negative other equity raises serious going-concern questions for shareholders; the stock is likely to face pressure given weak operational performance and no revenue growth visibility.